Jamshedpur Reporter

Cushing’s Syndrome Market Is Expected to Rise at a Significant CAGR During the Forecast Period | Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals

 Breaking News
  • No posts were found

Cushing’s Syndrome Market Is Expected to Rise at a Significant CAGR During the Forecast Period | Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals

June 17
18:35 2024
Cushing’s Syndrome Market Is Expected to Rise at a Significant CAGR During the Forecast Period | Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals
Cushing’s Syndrome Market 2032
According to DelveInsight, the market for Cushing’s Syndrome is poised for significant growth in the coming years. This growth is driven by an increasing prevalence of Cushing’s Syndrome patients across the 7 Major Markets (7MM), improvements in diagnostic methods, heightened disease awareness, enhanced governmental funding, robust research and development initiatives by pharmaceutical companies aimed at developing new therapies, and the introduction of emerging pipeline treatments.

DelveInsight’s “Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cushing’s Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Cushing’s Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Despite advancements in surgical and radiation therapy techniques, there remain substantial unmet medical needs in the treatment of patients with Cushing’s Syndrome. The anticipation of new therapeutic agents holds promise for potentially transforming the management of this complex condition. Key pharmaceutical companies like Corcept Therapeutics, Strongbridge Biopharma, AstraZeneca, among others, are actively engaged in developing novel therapies to address these unmet medical needs and enhance upon currently available treatments.

Recent breakthroughs in the Cushing Syndrome Market:

  • Isturisa (osilodrostat): The U.S. Food and Drug Administration (FDA) approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease. This approval is specifically for patients who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Isturisa directly addresses cortisol overproduction by blocking the enzyme 11-beta-hydroxylase, thus preventing cortisol synthesis. It is the first FDA-approved drug for this purpose.

  • Recorlev (levoketoconazole): Xeris Pharmaceuticals received orphan-drug exclusivity from the FDA for Recorlev (levoketoconazole), an approved treatment for adults with endogenous Cushing’s syndrome.

Key facts from the Cushing’s Syndrome Market Report:

  • The market for Cushing’s syndrome is poised for growth in the upcoming years, driven by the anticipated launch of potential therapies from key players such as Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, and others at various stages of development. With these therapies expected to gain approval during the forecast period (2023–2032), the overall therapeutic market for Cushing’s syndrome is projected to experience significant growth at a substantial compound annual growth rate (CAGR).

  • Other factors boosting the Cushing’s syndrome market include advancements in diagnostic solutions and novel product launches across the seven major markets. Emerging therapies leveraging innovative approaches like HSD-1 inhibitors and ACTH antagonists are expected to drive market expansion and potentially reduce the market share of Steroidogenesis inhibitors, which are less effective and associated with undesirable side effects.

  • The COVID-19 pandemic disrupted non-urgent medical services, including diagnostic tests and procedures, leading to delays in the diagnosis and treatment initiation for Cushing’s syndrome. This has had an impact on the overall Cushing’s syndrome market.

  • DelveInsight analysts have observed an increase in the incidence of Cushing’s syndrome in recent years. Given the limited late-stage pipeline products for the syndrome, there is a growing focus among companies on developing innovative therapies targeting endpoints beyond cortisol level reduction in the body.

Request for a detailed cushing’s syndrome market sample report: https://www.delveinsight.com/sample-request/cushings-syndrome-market

Cushing’s Syndrome Overview

Cushing’s syndrome is a rare disorder characterized by prolonged exposure to high levels of cortisol, a hormone produced by the adrenal glands. This excess cortisol can result from various causes, including the use of corticosteroid medications (exogenous Cushing’s syndrome) or from tumors that produce cortisol or adrenocorticotropic hormone (ACTH) (endogenous Cushing’s syndrome).

Cushing’s Syndrome Market Insights:

  • According to the Orphanet, the prevalence of endogenous Cushing’s Syndrome (CS) is 1/26,000, and in the EU, it has an annual prevalence of 1/1,400,000-1/400,000, with a peak prevalence at 25–40 years of age.

  • According to the “National Organization for Rare Disorders,” Cushing syndrome, caused by either an adrenal or pituitary tumor, affects females five times more frequently than males. Symptoms commonly begin between 25 and 40 years of age. Men are affected 3 times more than women by ectopic ACTH production caused by lung cancer, which occurs later in life.

  • According to the American Association of Neurological Surgeons, an estimated 10-15 per million people are affected with Cushing’s Syndrome yearly. Pituitary adenomas (Cushing’s disease) account for more than 70 percent of cases in adults and about 60-70 percent of cases in children and adolescents. Cushing’s syndrome most commonly affects adults ages 20-50 and is more prevalent in females, accounting for about 70 percent of all cases.

  • As per the National Organization for Rare Disorders, it is reported that the incidence of endogenous Cushing syndrome is approximately 13 per million people annually.

Cushing’s Syndrome Market Outlook

The global market for Cushing’s syndrome is projected to expand during the forecast period, focusing primarily on managing and treating the condition rather than achieving a cure. Factors driving this market outlook include advancements in diagnosis and treatment, ongoing research and development activities, increasing patient awareness, and evolving healthcare policies.

The incidence of Cushing’s syndrome has been on the rise, influenced by factors such as aging populations susceptible due to weakened immune systems and lifestyle factors. This trend supports market growth, bolstered further by continuous research efforts aimed at discovering new treatments or enhancing existing therapies. These advancements aim to improve treatment efficacy and safety across medications, surgical interventions, and radiation therapy, thereby broadening treatment options for patients.

Diagnosing Cushing’s syndrome accurately presents challenges as symptoms can overlap with other conditions, leading to underdiagnosis or misdiagnosis. Limited awareness among healthcare providers and access to specialized endocrine expertise can delay diagnosis, impacting market expansion. The high costs associated with diagnostic tests, medications, surgeries, and ongoing care also pose barriers. Surgical removal of tumors, when applicable, contributes significantly to treatment efficacy and market share.

Addressing these challenges necessitates a collaborative approach involving medical professionals, researchers, engineers, and specialists. Current treatment strategies for Cushing’s syndrome focus on symptom management and normalizing cortisol levels, but comprehensive cure options remain limited. This absence of definitive therapies and potential for disease recurrence can influence market dynamics and patient outcomes alike.

In conclusion, while advancements in research and healthcare infrastructure are driving market growth for Cushing’s syndrome, addressing diagnostic complexities, treatment costs, and the quest for curative approaches remain critical areas for improvement.

Cushing’s Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Cushing’s Syndrome Epidemiology, Segmented as –

  • Total Prevalent Cases of Cushing’s Syndrome in the 7MM (2019–2032)

  • Sub-type-specific Prevalence of Cushing’s Syndrome in the 7MM (2019–2032)

  • Age-specific Prevalence of Cushing’s Syndrome in the 7MM (2019–2032)

  • Gender-Specific Prevalence of Cushing’s Syndrome in the 7MM (2019–2032)

  • Diagnosed and Treatable Cases of Cushing’s Syndrome in the  7MM (2019–2032)

Cushing’s Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cushing’s Syndrome market or expected to be launched during the study period. The analysis covers Cushing’s Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers Cushing’s Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Cushing’s Syndrome Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/cushings-syndrome-market

Cushing Syndrome Marketed Drugs

  • ISTURISA (osilodrostat): Novartis/Recordati

  • KORLYM (mifepristone): Corcept Therapeutics

Cushing Syndrome Emerging Drugs

  • CRN04894: Crinetics Pharmaceuticals

  • SPI-62: Sparrow Pharmaceuticals

Leading Companies in the Cushing Syndrome Therapeutics Market Include:

  • Corcept Therapeutics

  • Crinetics Pharmaceuticals

  • Cyclacel Pharmaceuticals

  • Sparrow Pharmaceuticals

  • Stero Therapeutics

  • OMass Therapeutics

Table of Contents

1. Key Insights

2. Executive Summary 

3. Cushing’s Syndrome Competitive Intelligence Analysis

4. Cushing’s Syndrome Market Overview at a Glance

5. Cushing’s Syndrome Disease Background and Overview

6. Cushing’s Syndrome Patient Journey

7. Cushing’s Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Cushing’s Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Cushing’s Syndrome Unmet Needs

10. Key Endpoints of Cushing’s Syndrome Treatment

11. Cushing’s Syndrome Marketed Products

12. Cushing’s Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Cushing’s Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Cushing’s Syndrome Market Outlook (In US, EU5, and Japan)

16. Cushing’s Syndrome Access and Reimbursement Overview

17. KOL Views on the Cushing’s Syndrome Market

18. Cushing’s Syndrome Market Drivers

19. Cushing’s Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/